Yahong Pharmaceutical announced that the company's self-developed APL-2501 phase I/II clinical trial in advanced solid tumor patients completed the first patient enrollment. This drug is an anti-CLDN6/9 antibody drug conjugate independently developed by the company based on topoisomerase inhibitors, and can be used to treat various advanced solid tumors such as ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer. The study has been approved by the US FDA and the National Drug Administration, and this matter will not have a significant impact on the company's recent performance.

Yahong Pharmaceutical announced that the company's self-developed APL-2501 phase I/II clinical trial in advanced solid tumor patients completed the first patient enrollment. This drug is an anti-CLDN6/9 antibody drug conjugate independently developed by the company based on topoisomerase inhibitors, and can be used to treat various advanced solid tumors such as ovarian cancer, non-small cell lung cancer, endometrial cancer, and gastric cancer. The study has been approved by the US FDA and the National Drug Administration, and this matter will not have a significant impact on the company's recent performance.